By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators publish new report on Biotechnology. According to news reporting originating in Ithaca, New York, by NewsRx journalists, research stated, "We report the use of immuno-targeted gold-iron oxide hybrid nanoparticles for laser-assisted therapy and for MRI-based imaging as demonstrated in xenograft colorectal cancer tumor model. Immuno-targeted gold-iron oxide nanoparticles selectively accumulate in SW1222 xenograft tumors as compared to the accumulation in non-antigen-expressing tumor xenografts."
The news reporters obtained a quote from the research from Cornell University, "Effective photothermal treatment using near-IR laser irradiation (808nm, 5W cm(-2)) application is shown where >65% of the antigen-expressing tumor cells presented corrupt extracellular matrix and cytoplasmic acidophilia suggesting effectiveness of nanoparticle-assisted thermal therapy. Cell killing was confirmed by hematoxylin and eosin (H&E) histological staining where scar-like structure containing collagen bundles was observed in the treatment group. Further, systemically injected HNPs were shown to be effective T2 magnetic resonance (MR) imaging contrast agents, localized and detected at the antigen-expressing xenograft tumors. These findings suggest that the new class of bio-conjugated HNPs exhibits great potential for dual-therapy and diagnostics (theranostics) applications."
According to the news reporters, the research concluded: "This team reports the successful use of immuno-targeted gold-iron oxide hybrid nanoparticles for both laser-assisted therapy and MRI-based imaging in a xenograft colorectal cancer tumor model, demonstrating strong potentials for dual applications in cancer diagnosis and therapy."
For more information on this research see: Targeted near-IR hybrid magnetic nanoparticles for in vivo cancer therapy and imaging. Nanomedicine, 2013;9(5):702-11. (Elsevier - www.elsevier.com; Nanomedicine - www.elsevier.com/wps/product/cws_home/703416)
Our news correspondents report that additional information may be obtained by contacting D.K. Kirui, Graduate Field of Biomedical Engineering, 318 Stocking Hall, Cornell University, Ithaca, New York, United States. Additional authors for this research include I. Khalidov, Y. Wang and C.A Batt (see also technology.html">Biotechnology).
Keywords for this news article include: Biotechnology, Ithaca, Cancer, Therapy, New York, Oncology, Treatment, Xenograft, United States, Nanotechnology, Xenotransplantion, Emerging Technologies, Magnetic Nanoparticles, North and Central America.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC